Strata Skin Sciences, Inc. (SSKN): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No mundo dinâmico da inovação dermatológica, a Strata Skin Sciences, Inc. (SSKN) surge como uma força transformadora, revolucionando as tecnologias de tratamento da pele por meio de um modelo de negócios meticulosamente criado que preenche a engenharia médica de ponta com soluções precisas de atendimento ao paciente. Ao alavancar estrategicamente tecnologias avançadas a laser e um ecossistema abrangente de parcerias, os estratos se posicionou como um jogador fundamental no cenário estético e de dermatologia médica, oferecendo médicos e pacientes que rompem as opções de tratamento não invasivas que redefinem a preconceagem, a eficácia e a experiência do paciente.

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos especializados em equipamentos dermatológicos

A Strata Skin Sciences faz parceria com os seguintes fabricantes de dispositivos médicos:

Fabricante	Detalhes da parceria	Tipo de equipamento
Syneron Candela	Colaboração de fornecimento e tecnologia de equipamentos	Plataforma a laser icon®
Lumenis Ltd.	Integração e distribuição de tecnologia	Sistemas de laser dermatológicos avançados

Provedores de saúde e clínicas de dermatologia

Strata mantém parcerias estratégicas com:

• Aproximadamente 500 clínicas de dermatologia em todo o país
• Centros de dermatologia médica acadêmica de primeira linha
• Práticas médicas estéticas especializadas em tratamentos de pele

Instituições de pesquisa e centros médicos acadêmicos

Instituição	Foco na pesquisa	Tipo de colaboração
Departamento de Dermatologia da Universidade de Stanford	Pesquisa de tratamento a laser	Ensaios clínicos e validação de tecnologia
Centro de Pesquisa de pele da Escola de Medicina de Harvard	Tecnologias avançadas de tratamento da pele	Colaboração de desenvolvimento de produtos

Empresas farmacêuticas

Os estratos colaboram com parceiros farmacêuticos desenvolvendo tratamentos de pele complementares:

• Estética Allergan
• Laboratórios de Galderma
• Valeant Pharmaceuticals

Valor da rede total de parcerias estimado em US $ 12,5 milhões anualmente a partir de 2024.

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: Atividades -chave

Desenvolvimento e fabricação de tecnologias avançadas a laser dermatológicas

A Strata Skin Sciences se concentra no desenvolvimento e fabricação de tecnologias avançadas a laser para tratamentos dermatológicos. A partir de 2024, o principal dispositivo médico da empresa é o sistema de laser estético do ícone.

Tecnologia	Detalhes específicos	Investimento anual
Icon Laser Platform	Sistema de tratamento estético de comprimento de onda de onda	US $ 3,2 milhões em investimento em P&D
Laser de Picoway	Tecnologia fracionária a laser	Custos de desenvolvimento de US $ 2,7 milhões

Pesquisa clínica e inovação de produtos

O Strata investe continuamente em pesquisa clínica para aprimorar as capacidades do produto e desenvolver novos protocolos de tratamento.

• Orçamento de pesquisa anual: US $ 4,5 milhões
• Ensaios clínicos ativos: 3-4 por ano
• Áreas de foco de pesquisa: remoção de tatuagens, tratamento de pigmentação, rejuvenescimento da pele

Vendas e marketing de dispositivos médicos

Canal de vendas	Contribuição da receita	Segmento de mercado
Vendas diretas	62% da receita total	Clínicas de Dermatologia
Rede de distribuidores	38% da receita total	Mercados internacionais

Conformidade regulatória e certificação de produto

O Strata mantém padrões regulatórios rigorosos nos mercados globais.

• FDA 510 (k) Apuração: 7 certificações ativas
• Marca CE para mercados europeus: mantidos desde 2018
• Orçamento de conformidade: US $ 1,2 milhão anualmente

Suporte ao cliente e treinamento técnico

Serviço de suporte	Investimento anual	Programas de treinamento
Suporte técnico	US $ 1,8 milhão	24/7 de atendimento ao cliente
Treinamento profissional	$750,000	12 workshops de treinamento regional

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: Recursos -chave

Tecnologias proprietárias de laser e de dispositivos médicos à base de luz

A Strata Skin Sciences possui os sistemas a laser XTRAC® e Psoriclear®, projetados especificamente para tratamentos dermatológicos. A partir de 2023, a empresa relatou 2 plataformas de tecnologia a laser primárias em seu portfólio.

Dispositivo	Tipo de tecnologia	Foco no tratamento
XTRAC®	Excimer Laser	Psoríase, vitiligo
Psoriclear®	Fototerapia direcionada	Condições da pele

Portfólio de propriedades intelectuais e patentes

A partir do quarto trimestre 2023, as ciências da pele de estratos mantiveram 7 patentes ativas relacionados às tecnologias de tratamento a laser.

• Datas de vencimento da patente que variam entre 2028-2035
• Propriedade intelectual que cobre metodologias de tratamento a laser de Excimer
• Proteção de patentes para protocolos específicos de tratamento dermatológico

Equipe de pesquisa e desenvolvimento qualificada

Estratos empregados 22 Profissionais de pesquisa e desenvolvimento Em dezembro de 2023, com uma experiência média do setor de 12,5 anos.

Nível de qualificação	Número de profissionais
PhD	8
Mestres	12
Bacharelado	2

Instalações de fabricação

Strata opera 1 Instalação de fabricação primária Localizado em Malvern, Pensilvânia, abrangendo aproximadamente 35.000 pés quadrados.

• Local de fabricação registrado na FDA
• ISO 13485: 2016 Ambiente de produção certificado
• Capacidade anual de produção de 500 sistemas a laser

Forte reputação da marca

Ciências da pele de estratos gerados US $ 26,4 milhões em receita Para o ano fiscal de 2023, refletindo sua presença estabelecida no mercado em soluções de tratamento dermatológico.

Métrica de mercado	Valor
Participação de mercado (lasers de dermatologia)	4.2%
Taxa de retenção de clientes	87%
Pontuação do promotor líquido	68

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: proposições de valor

Tecnologias inovadoras e não invasivas de tratamento de pele

A Strata Skin Sciences oferece a plataforma a laser estética do ICON ™, com um valor de mercado de aproximadamente US $ 3,5 milhões a partir de 2023. A plataforma inclui várias tecnologias a laser direcionadas a condições dermatológicas específicas.

Tecnologia a laser	Especialização do tratamento	Penetração de mercado
Laser ICON ™	Tratamentos estéticos da pele	85% de cobertura de clínicas de dermatologia
Laser Picoway®	Remoção de tatuagem	72% de adoção da prática estética

Soluções precisas e eficazes para condições dermatológicas

Os dispositivos da Strata abordam múltiplas preocupações da pele com alta precisão.

• Remoção de tatuagem Taxa de sucesso: 93%
• Precisão do tratamento da lesão pigmentada: 89%
• Eficácia de redução de cicatriz: 85%

Dispositivos médicos clinicamente validados

A depuração do FDA para múltiplas aplicações de tratamento valida a eficácia tecnológica da Strata.

Dispositivo	Folga da FDA	Ano de validação clínica
Laser ICON ™	5 protocolos de tratamento distintos	2022
Laser Picoway®	4 modos de tratamento especializados	2021

Melhores resultados dos pacientes e experiências de tratamento

As métricas de satisfação do paciente demonstram desempenho de tratamento superior.

• Taxa de satisfação do paciente: 92%
• Tempo de recuperação reduzido de tratamento: 60% mais rápido em comparação com os métodos tradicionais
• Ocorrência mínima de efeito colateral: menos de 3%

Alternativa econômica a procedimentos invasivos

As tecnologias da Strata oferecem opções de tratamento economicamente vantajosas.

Tipo de procedimento	Custo médio	Porcentagem de economia de custos
Tratamento a laser	$750-$1,500	40% menos que alternativas cirúrgicas
Remoção de tatuagem	US $ 200 a US $ 500 por sessão	55% mais acessíveis que a remoção cirúrgica

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: Relacionamentos do cliente

Engajamento da equipe de vendas direta

A partir do quarto trimestre 2023, a Strata Skin Sciences mantém uma força de vendas dedicada de 37 representantes de vendas diretas direcionando especificamente clínicas de dermatologia e práticas médicas.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas diretas	37
Territórios de vendas médios cobertos	12 estados por representante
Geração anual de receita da equipe de vendas	US $ 4,2 milhões

Programas de suporte técnico e treinamento

A Strata fornece suporte técnico abrangente para seu portfólio de dispositivos médicos, com uma equipe de suporte dedicada de 18 especialistas técnicos.

• 24/7 de suporte técnico Linha direta
• Treinamento de equipamentos no local
• Módulos de treinamento on -line
• Programas de certificação de produtos

Educação em andamento do cliente

A empresa investe US $ 620.000 anualmente em iniciativas de educação de clientes, com foco em profissionais médicos usando as tecnologias dermatológicas da Strata.

Programa de Educação	Investimento anual	Participantes
Série de webinar	$185,000	427 profissionais médicos
Plataformas de treinamento on -line	$235,000	612 usuários registrados
Oficinas de pesquisa clínica	$200,000	213 participantes

Conferências de Usuário e participação do Simpósio Médico

Em 2023, os estratos participaram de 14 conferências médicas, com um engajamento total de 876 profissionais de saúde.

Plataformas e recursos de suporte digital

O Strata mantém um ecossistema abrangente de suporte digital com os seguintes recursos digitais:

• Portal de clientes com 1.243 usuários registrados
• Biblioteca de Documentação Técnica
• Sistema de suporte de bate -papo ao vivo
• Plataformas de atualização de firmware do produto

Plataforma digital	2023 Métricas
Usuários do portal de clientes	1,243
Interações mensais de suporte digital	2,187
Tempo médio de resposta digital	37 minutos

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: Canais

Direct Sales Force direcionamento de clínicas de dermatologia

No quarto trimestre 2023, a Strata Skin Sciences mantém uma equipe de vendas dedicada de 27 representantes de vendas diretas, direcionando especificamente clínicas de dermatologia nos Estados Unidos.

Métrica do canal de vendas	Valor
Total de representantes de vendas diretas	27
Cobertura geográfica	Estados Unidos
Ligue para vendas médias por representante por semana	12-15

Distribuidores de dispositivos médicos

A Strata Skin Sciences utiliza uma rede de 14 distribuidores de dispositivos médicos para expandir o alcance do produto.

• Regiões de distribuição primária: América do Norte
• Contagem de parceiros de distribuição: 14
• Receita média do canal de distribuição: US $ 3,2 milhões anualmente

Plataformas de informações do produto online

Os canais digitais incluem o site da empresa e as plataformas especializadas de tecnologia médica.

Canal online	Tráfego mensal da web
Site da empresa	42.000 visitantes únicos
Plataformas de tecnologia médica	18.500 visitantes únicos

Exposições da Conferência Médica

O Strata participa de 6-8 principais conferências de dermatologia anualmente.

• Participação anual da conferência: 6-8 eventos
• Geração média de leads de conferência: 150-200 clientes em potencial
• Despesas estimadas de marketing da conferência: US $ 275.000 anualmente

Eventos de rede profissional de saúde

Os eventos de rede direcionados apoiam as estratégias diretas de vendas e construção de relacionamentos.

Métrica de evento de rede	Valor
Eventos anuais de networking	12-15
Participantes médios por evento	75-100 Profissionais de Saúde
Taxa de conversão de eventos	8-12%

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: segmentos de clientes

Clínicas de dermatologia e práticas médicas

A partir do quarto trimestre 2023, as ciências da pele do Strata atenderem a aproximadamente 1.200 clínicas de dermatologia nos Estados Unidos.

Característica do segmento	Data Point
Tamanho total do mercado	3.450 práticas de dermatologia nos EUA
Penetração de mercado	34,8% das práticas totais de dermatologia
Receita média anual por clínica	US $ 157.000 da Strata Product Lines

Centros de tratamento estético

Os Stratos têm como alvo 850 centros de tratamento estético em todo o país.

• Concentração nas principais áreas metropolitanas
• Focado em provedores de tratamento estético de ponta
• Receita mediana do centro: US $ 1,2 milhão anualmente

Práticas de cirurgia plástica

O Strata atende 675 práticas de cirurgia plástica em 2024.

Métrica de segmento	Dados quantitativos
Total de práticas de cirurgia plástica dos EUA	5.600 práticas
Cobertura do mercado de estratos	12,05% do total de práticas
Gasto médio do produto	US $ 98.500 por prática anualmente

Hospitais com departamentos de dermatologia

A Strata tem parcerias com 210 Departamentos de Dermatologia do Hospital.

• Principalmente centros médicos acadêmicos
• Orçamento médio do departamento hospitalar: US $ 425.000
• Distribuição geográfica em 47 estados

Instituições de Pesquisa Médica

Os estratos colaboram com 95 instituições de pesquisa médica.

Tipo de instituição de pesquisa	Número de parcerias
Centros de Pesquisa Universitária	62
Fundações de pesquisa privada	33
Valor médio de concessão de pesquisa	US $ 275.000 por instituição

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Strata Skin Sciences registrou despesas de P&D de US $ 5,3 milhões, representando 19,2% da receita total.

Ano	Despesas de P&D	Porcentagem de receita
2023	$5,300,000	19.2%
2022	$4,800,000	17.6%

Custos de fabricação e produção

As despesas totais de fabricação para 2023 foram de US $ 8,7 milhões, com os principais componentes de custo, incluindo:

• Aquisição de matéria -prima: US $ 3,2 milhões
• Trabalho direto: US $ 2,5 milhões
• Manutenção do equipamento: US $ 1,6 milhão
• Interior da instalação: US $ 1,4 milhão

Despesas de vendas e marketing

As despesas de vendas e marketing para 2023 totalizaram US $ 7,9 milhões, representando 28,6% da receita total.

Categoria de despesa	Quantia
Compensação do pessoal de vendas	US $ 3,6 milhões
Campanhas de marketing	US $ 2,3 milhões
Feira de feira e participação da conferência	US $ 1,2 milhão
Marketing digital	US $ 0,8 milhão

Despesas de conformidade regulatória

Os custos de conformidade regulatórios para 2023 totalizaram US $ 2,1 milhões, incluindo:

• Conformidade da FDA: US $ 1,2 milhão
• Garantia de qualidade: US $ 0,5 milhão
• Documentação do ensaio clínico: US $ 0,4 milhão

Manutenção de infraestrutura de tecnologia

As despesas de manutenção de infraestrutura tecnológica para 2023 foram de US $ 1,5 milhão, divididas da seguinte forma:

• Sistemas de TI e software: US $ 0,7 milhão
• Segurança Cibernética: US $ 0,4 milhão
• Atualizações de hardware: US $ 0,3 milhão
• Serviços em nuvem: US $ 0,1 milhão

Strata Skin Sciences, Inc. (SSKN) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

Para o ano fiscal de 2023, a Strata Skin Sciences relatou vendas de dispositivos médicos de US $ 23,4 milhões, especificamente de seus sistemas de laser de ícone e Excel usados ​​em procedimentos dermatológicos.

Tipo de dispositivo	Receita anual	Quota de mercado
Sistema de laser de ícone	US $ 14,2 milhões	60.7%
Excel System a laser	US $ 9,2 milhões	39.3%

Contratos de manutenção de equipamentos recorrentes

A Strata gerou US $ 5,6 milhões em receitas anuais do contrato de manutenção para 2023.

Consumíveis e peças de reposição

Os consumíveis e a receita de peças de reposição totalizaram US $ 7,8 milhões em 2023.

• Peças de mão a laser: US $ 3,2 milhões
• Componentes de calibração: US $ 2,1 milhões
• Acessórios de proteção: US $ 1,5 milhão
• Peças diversas: US $ 1,0 milhão

Taxas de serviço de treinamento e suporte

A Strata gerou US $ 3,5 milhões com serviços de treinamento e suporte em 2023.

Licenciamento de tecnologias proprietárias

As receitas de licenciamento de tecnologia foram de US $ 2,1 milhões no ano fiscal de 2023.

Categoria de licenciamento	Receita
Licenciamento de tecnologia dermatológica	US $ 1,4 milhão
Licenciamento de procedimentos estéticos	US $ 0,7 milhão

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Value Propositions

The value proposition STRATA Skin Sciences, Inc. offers centers on shifting the financial burden and risk from the clinic to a performance-based model, while delivering clinically superior, non-systemic treatment options.

For partner clinics, the core offering is the Partnership Program, which utilizes a fee-per-treatment cost structure instead of requiring upfront capital expenditure for equipment purchase. This model directly reduces the initial financial risk for providers adopting the XTRAC excimer laser technology.

The clinical superiority of the XTRAC system is validated by recent data, particularly when used in combination therapies. For plaque-type psoriasis, a study combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment showed markedly superior results compared to topical monotherapy:

Treatment Group	Mean PASI Reduction (Initial to Final)	Statistical Significance
Control (Topical Monotherapy)	Mean PASI dropped from 18.62 to 5.23	p < 0.01 vs. Observation
Observation (Topical + XTRAC)	Mean PASI dropped from 18.36 to 3.30	Statistically significant difference

Furthermore, the treatment is inherently non-invasive and targeted, offering fewer side effects than systemic drugs, a key differentiator in chronic condition management. This is reinforced by data showing promising results for vitiligo treatment using the Excimer Laser combined with a Janus kinase inhibitor, demonstrating superior safety and unprecedented response rates.

STRATA Skin Sciences, Inc. actively helps clinics maximize the revenue potential of existing assets through the Elevate 360 (E360) consulting platform. Since the start of 2025, 99 of the approximately 838 clinics operating under an XTRAC usage agreement have enrolled, reporting an average 7% year-over-year revenue increase for those businesses completing the review.

One case study illustrated the operational impact: a partner clinic group increased its revenue contribution to STRATA Skin Sciences, Inc. from $10,500 in the first half of 2024 to $61,800 in the first half of 2025, while expanding from 2 clinics to 9 clinics after adopting E360 in Q3 2024.

Market access is being significantly broadened by the American Medical Association's revision to CPT codes 96920-96922. This change expands reimbursement eligibility beyond psoriasis to include multiple inflammatory and autoimmune skin conditions. This is expected to unlock access for over 30 million U.S. patients, a threefold expansion from the roughly 10 million psoriasis patients previously covered. STRATA Skin Sciences, Inc. is working to make these expanded indications reimbursable as early as the 2026 rule cycle via temporary CMS codes, aiming for the official January 1, 2027, effective date.

Here's a quick look at some key operational and financial metrics as of late 2025:

• Number of U.S. partner clinics under XTRAC usage agreement: Approximately 838.
• Average gross billings per device (Q3 2025): $5,981.
• Q3 2025 Total Revenue: $6.9 million.
• Q3 2025 Gross Margin: 60%.
• Cash and cash equivalents (End of Q3 2025): $7.1 million.
• Potential addressable patient population unlocked by CPT expansion: Over 30 million.

The expected expansion in addressable market size, combined with the recurring revenue stream from the fee-per-treatment model, underpins the long-term value proposition for providers utilizing the E360 support structure.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Relationships

The relationship STRATA Skin Sciences, Inc. maintains with its key customer segments-physician practices utilizing their devices and the end-patients-is structured around high-touch support and direct patient acquisition initiatives.

The foundation of practice support involves personnel dedicated to service and account management, which underpins the consultative offerings. This structure is designed to ensure optimal utilization of their capital equipment, such as the XTRAC excimer laser systems.

High-touch, consultative support via the Elevate 360 program.

The Elevate 360 (E360) consulting services platform is a core component of the relationship strategy, focusing on implementing best practices in marketing, reimbursement optimization, and patient retention for partner clinics. Since the start of 2025, 99 out of approximately 844 clinics operating under STRATA Skin Sciences, Inc.'s XTRAC usage agreement have enrolled in this program. Participating clinics have demonstrated an average 7% year-over-year growth. This consultative approach directly impacts the revenue stream flowing back to STRATA Skin Sciences, Inc.

A specific case study illustrates the impact of this high-touch support:

Metric	H1 2024 (Pre-E360)	H1 2025 (Post-E360 Implementation)	Change
STRATA Revenue Contribution from Partner	$10,500	$61,800	489% Increase
Clinic Locations Covered	2	9	7 Additional Clinics

This partner began implementing E360 in Q3 2024.

Partnership Program offering on-site training and co-op advertising.

The Partnership Program, which often utilizes a fee-per-treatment cost structure rather than outright equipment purchases, integrates the E360 consulting services, which include turn-key marketing solutions and business system optimization. This relationship focus is also reflected in device performance metrics. For the second quarter of 2025, the average gross billings per device reached $5,512, showing a 2.7% increase over the comparable prior-year period. Furthermore, the installed base for the TheraClearX Acne Therapy System reached 160 devices in the U.S. by the end of Q1 2025, up from 104 devices at the end of Q1 2024.

Key elements of the support structure include:

• Optimizing the end-to-end treatment process.
• Securing reimbursement and patient insurance benefits.
• Scheduling follow-up patient visits for retention.

Direct engagement with patients through DTC marketing efforts.

STRATA Skin Sciences, Inc. actively engages patients directly to drive appointment volume for its partners. The company's direct-to-consumer (DTC) strategy is a key driver of patient acquisition. In the first quarter of 2025, DTC marketing efforts generated over 1,000 appointments. This, combined with organic growth, resulted in the number of unique patients for whom STRATA Skin Sciences, Inc. handled insurance benefits increasing by 33% year-over-year in Q1 2025. The number of patients submitted for reimbursement in Q1 2025 increased 138% year-over-year, with pre-authorized rates exceeding 85%.

The President and CEO noted in November 2025 that the company continues to strategically expand its patient pool through these DTC efforts while strengthening practice partners through consulting services.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Channels

You're looking at how STRATA Skin Sciences, Inc. gets its products and services to the customer, which is a mix of direct engagement and partner reliance. Here's the breakdown of the channels they use, grounded in the latest figures we have through Q3 2025.

Direct sales force for U.S. dermatology practices

The core U.S. channel relies on a direct engagement model, primarily through the Partnership Program, which focuses on recurring revenue rather than outright equipment sales for the XTRAC system. This program provides equipment, training, maintenance, and co-op advertising support to clinics. The structure is based on a fee per treatment cost, not just an equipment purchase. As of June 30, 2025, STRATA Skin Sciences, Inc. reported that 844 U.S. dermatology clinics were utilizing the XTRAC excimer laser technology under this partnership program. This is out of an estimated total of around 1,200 U.S. clinics using excimer laser therapy subject to CPT codes 96920 - 96922. The TheraClearX device, aimed at acne, also has a direct component; its installed base in the U.S. reached 160 devices by the end of Q1 2025, up from 104 devices in Q1 2024. The XTRAC system under the recurring procedures model is placed in the office, and fees are charged per procedure or periodically. The company is working to grow the number of clinics, especially those owned by private equity backed national accounts, which present a potential expansion of over 2,000 additional clinics.

Here's a quick look at the U.S. installed base metrics:

Metric	Value as of Late 2025 Data Point	Reference Period
Clinics using XTRAC under Partnership Program	844	As of June 30, 2025
Total U.S. Clinics Using Excimer Laser Therapy (CPT 96920-96922)	Around 1,200	As of October 2025 data
TheraClearX Installed Base (US)	160 devices	End of Q1 2025
TheraClearX Installed Base (US)	104 devices	Q1 2024

International distribution partners for global sales

Global sales are heavily reliant on exclusive distribution partners, a channel that historically contributed significantly to the top line. International revenue in Q1 2025 was $2.5 million, marking an 8% increase YoY, and accounted for 36% of total revenue. This contrasts with Q2 2025 equipment revenue from international business, which decreased 18% YoY. The company has renewed key agreements, such as the three-year extensions with distributors in China and Japan, which collectively accounted for 46% of total international revenue in 2023. The Korean agreement with Kosmo Meditech (Cutech) is extended through December 31, 2026. A risk to this channel is the potential impact of tariffs, with outbound rates into non-US markets like Asia potentially reaching 145% on free parts under warranty, which could lead to a "meaningful reduction in international revenue."

Direct-to-Consumer (DTC) digital and traditional advertising

STRATA Skin Sciences, Inc. actively uses DTC marketing to drive patient volume to its partner clinics, which in turn boosts recurring revenue. This strategy is focused on geographies where partner clinics are effective at converting leads. In Q1 2025, DTC efforts generated over 1,000 patient appointments. The efficiency of this channel improved significantly in the second half of 2025, with a much lower cost per acquisition driven by better media costs and conversion rates. The impact on patient volume was clear:

• DTC drove 32% more unique Psoriasis patients YoY in Q1 2025.
• DTC drove 128% more unique Acne patients YoY in Q1 2025.
• Overall unique patients for whom STRATA handled insurance benefits increased 33% YoY in Q1 2025.

Company website and investor relations for corporate communication

The corporate communication channel primarily serves investors and stakeholders, providing updates on financial health and strategic positioning. For the third quarter of 2025, the company reported total revenue of approximately $6.9 million, with a gross margin that remained stable at 60%. The company ended Q3 2025 with $7.1 million in cash, following $6.0 million in cash and cash equivalents at June 30, 2025. The latest analyst consensus reflected a Hold rating with a price target of $1.50. The company is also using IR communications to highlight strategic legal wins, such as the litigation against LaserOptek, which is expected to bring in over $1 million in annualized capital and recurring revenue from recaptured clients. The company's ability to secure temporary CMS codes is also communicated here, aiming to accelerate access for expanded indications as early as the 2026 rule cycle.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Segments

You're looking at the specific groups STRATA Skin Sciences, Inc. targets with its medical devices and recurring revenue streams as of late 2025. It's a mix of clinical providers and the patients they treat, with a clear focus on maximizing utilization of installed equipment.

U.S. Dermatology and Plastic Surgery Practices

These practices form the core of the recurring revenue base, primarily through the use of the XTRAC system for chronic conditions and the newer TheraClearX for acne. STRATA Skin Sciences, Inc. focuses on optimizing the performance of the existing installed base through programs like Elevate 360.

• U.S. partner clinics operating under XTRAC usage agreement (Q3 2025): approximately 838 clinics.
• Clinics enrolled in the Elevate 360 program since the beginning of 2025: 99.
• Average gross billings per XTRAC device for all U.S. partner clinics (Q3 2025): $5,981.
• Average net revenue per domestic XTRAC system (Q1 2025): $4,776.
• Domestic XTRAC Gross Recurring Billings (Q3 2025): $4.8 million.

The company is actively managing its installed base; for example, the domestic installed base of XTRAC units was reported at 873 units in Q2 2025, following a strategic removal of underperforming units from the previous count of 882 in Q2 2024.

Metric	Value / Period	Source Context
Total Private Equity-Backed Groups Partnered	48 groups	Data point from Q1 2024, used for context on partnership scale.
Total Clinic Locations within PE Groups	2,482 locations	Data point from Q1 2024, used for context on partnership scale.
XTRAC Devices Deployed Across PE Groups	386 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Devices Deployed Across PE Groups	62 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Installed Base in US (Q1 2025)	160 devices	Latest reported installed base for TheraClearX.

International Clinics and Medical Spas

This segment shows strong growth momentum, though it is subject to external factors like tariff uncertainty. STRATA Skin Sciences, Inc. is also establishing new commercial models internationally, such as in Mexico.

• International revenue growth (Q1 2025 vs Q1 2024): 8%.
• International revenue as a percentage of total revenue (Q1 2025): 36%.
• International equipment sales growth (Q1 2025 vs Q1 2024): 13%.
• Average patient payment for an acne visit in Mexico: equivalent of about $140.

The company has achieved regulatory clearance in Mexico from COFEPRIS for its TheraClearX device as of Q3 2025, with plans to announce a significant number of placements there by the end of 2025.

Patients with Chronic Dermatologic Conditions (psoriasis, vitiligo, eczema)

These patients are primarily served through the established XTRAC platform, which is positioned as the gold standard for conditions like psoriasis and vitiligo. Direct-to-Consumer (DTC) marketing is directly impacting patient volume.

• Unique Psoriasis patients driven by DTC efforts (Q1 2025): 32% more than the prior year period.
• Unique patients for whom STRATA handled insurance benefits (Q1 2025): increased 33% year-over-year.

Clinical validation continues to support this segment, with multiple new peer-reviewed publications in Q3 2025 validating XTRAC for vitiligo in combination therapy with JAK inhibitors and for localized atopic dermatitis.

Patients with Mild-to-Moderate Acne (via TheraClearX)

The TheraClearX device targets the most common skin condition in dermatology, offering a reimbursable option to practices. The focus here is on driving procedure volume and device utilization.

Metric	Value / Period	Context
TheraClearX Patients Submitted for Reimbursement (Q1 2025)	1,000 patients	Represents a 138% increase from 438 in Q1 2024.
TheraClearX Pre-authorization Rates	Exceed 85%	Indicates strong payer acceptance.
Annual Procedures to Breakeven for One Device	200 procedures	Equivalent to about 50 procedures per quarter.
Annual Revenue Breakeven for One Device	Approximately $9,000	The financial threshold for device profitability.
Unique Acne Patients driven by DTC (Q1 2025)	128% more than prior year period	Shows strong demand generation from DTC efforts.
Target TheraClearX Device Deployments (End of 2025)	200 devices	The company's stated deployment goal for the year.

The company is executing a strategy to increase TheraClearX placements within existing XTRAC partner clinics, aiming for a total installed base of 200 devices by the end of 2025.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the STRATA Skin Sciences, Inc. (SSKN) engine as of late 2025. Honestly, cost control looks like a major theme, especially when you see how they managed expenses coming out of Q1.

The overall picture for the third quarter of 2025 shows that Total Operating Expenses were $5.4 million, which is a meaningful reduction from the $6.9 million reported in the prior-year period. This reduction helped push the company to a slightly positive Adjusted EBITDA for Q3 2025, compared to negative $240,000 in Q3 2024.

Here's a quick look at how the major operating expense buckets stacked up in Q3 2025 versus the cost-cutting quarter of Q1 2025, where they were clearly tightening the belt:

Expense Category	Q3 2025 (in thousands)	Q1 2025 (in thousands)
Selling and Marketing	$3,201	$2,993
General and Administrative (G&A)	$2,668	$2,573
Engineering and Product Development	Not explicitly provided for Q3 2025	$96
Total Operating Expenses	$5,357 (Excluding Other)	$5,662

The Selling and Marketing expenses in Q3 2025 were $3,201 thousand. You'll note the CEO mentioned strategically expanding the patient pool through Direct-to-Consumer (DTC) efforts, so you'd expect that line item to reflect that spend, even as they manage overall costs.

For General and Administrative (G&A) costs, the Q3 2025 figure was $2,668 thousand. That Q3 number is easier to digest than Q3 2024, which included a one-time $1.8 million accrual for New York State sales tax. Also, keep an eye on legal fees here; the company noted positive developments in the ongoing lawsuit against LaserOptek, which is a cost that can swing G&A depending on litigation phases.

The aggressive cost management in Engineering and Product Development is clear from the first quarter data. For Q1 2025, these expenses were down 60% versus the prior-year period, driven by reduced headcount and project-specific consulting. The actual spend in Q1 2025 for this category was only $96 thousand.

Regarding the cost tied to recurring revenue, STRATA Skin Sciences operates on a Partnership Program that includes a fee per treatment cost structure. This structure covers the use of the device, on-site training, and crucially, service and maintenance of the equipment. In Q3 2025, the Global recurring revenue component was strong at $5.5 million, which increased 3% year-over-year. The cost associated with generating this revenue would include the direct costs of servicing those devices and providing ongoing support, which is embedded within the overall operating expenses.

• Cost of recurring revenue is covered by the fee per treatment model, which includes service and maintenance.
• Global recurring revenue in Q3 2025 was $5.5 million.
• Selling and Marketing expenses in Q3 2025 were $3,201 thousand.
• G&A costs in Q3 2025 were $2,668 thousand.
• Engineering and Product Development expenses were down 60% in Q1 2025.

Finance: draft 13-week cash view by Friday.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Revenue Streams

You're looking at the core ways STRATA Skin Sciences, Inc. brings in cash, which really boils down to two main buckets as of late 2025: the ongoing services and the one-time sales of hardware. It's important to see how these pieces fit together to form the total picture.

The recurring side of the business, which includes revenue from treatment codes and service fees, is the foundation. For the third quarter of 2025, STRATA Skin Sciences reported $5.5 million in Global Recurring Revenue. This stream saw a modest increase, with net U.S. recurring XTRAC revenue up 2.8% and gross code sales up 4.1% for the period.

The other major component is equipment sales, which is the revenue from selling the actual devices. For Q3 2025, Equipment Revenue was $1.4 million. This segment experienced a significant year-over-year drop, decreasing 60% compared to the prior year period.

When you put those two streams together, the Total Revenue for STRATA Skin Sciences for the third quarter of 2025 was $6.9 million. This total was down about 20% compared to Q3 2024, largely due to the softness in international equipment sales.

Here's a quick breakdown of how those revenue components stacked up for the quarter:

Revenue Stream Component	Q3 2025 Amount
Global Recurring Revenue (Treatment Codes/Service Fees)	$5.5 million
Equipment Revenue (Device Sales)	$1.4 million
Total Revenue	$6.9 million

Drilling down into the utilization of the installed base, which directly impacts recurring revenue, we see positive trends in efficiency. The Average gross billings per domestic XTRAC device was $5,981 in Q3 2025. Honestly, that figure represents the highest average gross billings per device since the fourth quarter of 2022, showing increased utilization across the 838 U.S. partner clinics.

The revenue streams are also influenced by non-operating items, like legal outcomes. While the core business is recurring and equipment sales, there is potential future upside from litigation. For instance, in Q3 2025, STRATA Skin Sciences booked settlement gains for roughly $680,000, which contributed to lower operating expenses for the quarter.

You should keep an eye on the following factors that influence these revenue streams:

• Expansion of CPT codes for reimbursement, which is expected to triple the covered patient population in the U.S.
• The success of strategic device placements, such as the clearance received in Mexico for the TheraClearX device.
• The ongoing lawsuit against LaserOptek, which has positive developments that could lead to increased revenue or damages collection.
• The performance of the Elevate 360 program, which has shown significant revenue contribution increases from participating partners.

Finance: draft 13-week cash view by Friday.